Provided by Tiger Trade Technology Pte. Ltd.

ProQR Therapeutics NV

1.38
-0.0400-2.82%
Volume:653.13K
Turnover:904.35K
Market Cap:145.38M
PE:-2.86
High:1.44
Open:1.42
Low:1.34
Close:1.42
52wk High:3.10
52wk Low:1.07
Shares:105.35M
Float Shares:67.53M
Volume Ratio:2.32
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4823
EPS(LYR):-0.3339
ROE:-103.76%
ROA:-24.02%
PB:2.15
PE(LYR):-4.13

Loading ...

ProQR Therapeutics kündigt Wechsel im Vorstand an

Reuters
·
Feb 09

BRIEF-Proqr Announces Encouraging Ax-0810 Phase 1

Reuters
·
Jan 08

ProQR Reports Positive Initial Safety Data from AX-0810 Phase 1 Trial

Reuters
·
Jan 08

ProQR Therapeutics Nv: Initial Ax-0810 Data Show No Safety Signals After 4 Weeks of Dosing and Pharmacokinetics Consistent With Non-Clinical Data

THOMSON REUTERS
·
Jan 08

ProQR Therapeutics Nv: Phase 1 Ax-0810 Data Expected in H1 2026

THOMSON REUTERS
·
Jan 08

ProQR Therapeutics to Participate in Evercore Healthcare Conference

Reuters
·
Dec 01, 2025

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 29% Share Price Plunge Could Signal Some Risk

Simply Wall St.
·
Nov 24, 2025

ProQR Therapeutics Q3 EPS EUR -0.1

Reuters
·
Nov 20, 2025

ProQR Q3 revenue misses estimates, reports net loss

Reuters
·
Nov 06, 2025

BRIEF-ProQR Therapeutics Q3 EPS EUR -0.1

Reuters
·
Nov 06, 2025

ProQR Therapeutics Q3 Revenue EUR 2.882 Million VS. Ibes Estimate EUR 4.37 Million

THOMSON REUTERS
·
Nov 06, 2025

ProQR Therapeutics NV expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
Oct 31, 2025

ProQR Therapeutics NV held annual shareholder meeting

Reuters
·
Oct 24, 2025

ProQR Therapeutics Receives CTA Authorization for Phase 1 Trial of AX-0810 in Europe

Reuters
·
Oct 20, 2025

ProQR Therapeutics Nv - Receives Cta Authorization for Phase 1 Study of Ax-0810

THOMSON REUTERS
·
Oct 20, 2025

ProQR Therapeutics NV to Participate in Chardan's Annual Genetic Medicines Conference

Reuters
·
Oct 13, 2025

ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Price Is Out Of Tune With Revenues

Simply Wall St.
·
Oct 10, 2025